# Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

> **NCT02256787** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BILB 1941 ZW - single rising dose part
- **DRUG:** Placebo
- **DRUG:** BILB 1941 ZW - solution
- **DRUG:** BILB 1941 ZW - tablet
- **OTHER:** standardized breakfast

## Key facts

- **NCT ID:** NCT02256787
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-09
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2014-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02256787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02256787, "Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02256787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*